glp-1 and gip receptor agonist Understand GLP-1/GIP Dual Tirzepatide Its Effect on Current Weight Loss Therapy Science Behind GLP 1 GIP

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging class of glucose-lowering drugs that are increasingly used in the treatment of type 2 diabetes (T2D) and obesity

With rising global obesity rates, simpler and more accessible treatments like oral GLP-1 drugs could shape the next phase of growth in this segment

Larger reductions in A1c were generally seen with higher doses of SGLT2-I and amongst patients with higher baseline A1c values

Introduction The glucagon-like peptide-1 (GLP-1) is a 3031 amino acid incretin secreted by enteroendocrine L cells in the ileum and colon in response to nutritional stimuli such as glucose, fatty acids, and amino acids in the intestinal lumen

In people with T2D, the incretin effect is severely attenuated, despite similar levels of circulating GLP-1

doi: 10.1038/s42255-023-00812-z